Citations

Clear

116 citation(s) found for "Colby, Thomas".

Diagnosis of Hypersensitivity Pneumonitis
Beasley, Mary Beth , Colby, Thomas V. , Lynch, David, Müller, Néstor L. , Yang, Soo-Ryum , Churg, Andrew , Pérez, Evans R. Fernández , Travis, William D.

Mayo Clinic

American Journal of Surgical Pathology | November 10, 2021 | Volume: 46 | Issue: 4 | Pages: e71-e93

10.1097/pas.0000000000001827 | PMID 34753865 Get It

Assessment of lung biopsies for the diagnosis of hypersensitivity pneumonitis (HP) is one of the most difficult diagnostic problems for surgical pathologists. It is a form of interstitial lung disease resulting from an immune reaction provoked by an inhaled antigen in susceptible individuals. Although this definition sounds simple, in practice, the diagnosis of HP can be challenging. To address these issues, the American College of Chest Physicians (CHEST) has recently published a guideline for the diagnosis of HP. In this review, we will explore the multidisciplinary diagnostic evaluation of HP with a focus on the pathologic features as outlined in the CHEST guidelines. The histologic criteria are divided into 4 diagnostic categories: (1) Typical nonfibrotic HP or fibrotic HP; (2) Compatible with nonfibrotic HP or fibrotic HP; (3) Indeterminate for nonfibrotic or fibrotic HP; and (4) Alternative Diagnosis. It is important to emphasize that patterns 1 to 3 do not represent discrete histologic entities or pathologic diagnoses. Rather, these categories are meant to serve as a practical guide for organizing a complex set of overlapping histologic patterns into an integrated diagnostic framework for facilitating multidisciplinary discussion. High-resolution computed tomography features are also summarized, emphasizing how the correlation of lung biopsies with computed tomography findings can help to favor the diagnosis, particularly in cases where biopsies are not typical for HP. This review highlights details of the histologic spectrum of HP as well as the utility of different types of biopsies and bronchoalveolar lavage. We also emphasize the importance of multidisciplinary discussion and the complex differential diagnosis.
Impact of Lung Biopsy Information on Treatment Strategy of Patients with Interstitial Lung Diseases
Tomassetti, Sara , Ravaglia, Claudia , Ryu, Jay H. , Colby, Thomas V. , Wells, Athol U. , Pavone, Mauro, Matucci‐Cerinic, Marco , Rosi, Elisabetta , Luzzi, Valentina , Gori, Leonardo , Rossi, Giulio , Donati, Luca, Dubini, Alessandra, Piciucchi, Sara , Piciucchi, Sara , Ryu, Jay H , Ravaglia, Claudia , Puglisi, Silvia , Vancheri, Carlo , Lavorini, Federico , Poletti, Venerino

Mayo Clinic

Annals of the American Thoracic Society | November 5, 2021 | Volume: 19 | Issue: 5 | Pages: 737-745

10.1513/annalsats.202104-466oc | PMID 34739359 Get It

Abstract Rationale Lung biopsy (LBx) has a relevant role in the prediction of prognosis of interstitial lung diseases (ILDs), but its impact on the clinical management of patients remains unexplored. Objectives This study evaluates whether LBx may change the therapeutic strategy and assesses the effect of diagnostic reclassification after LBx on long-term prognosis. Methods We evaluated the LBx of 426 consecutive patients with ILDs, without a definite usual interstitial pneumonia pattern on high-resolution computed tomographic imaging. A total of 266 patients underwent transbronchial lung cryobiopsy (TBLC), and 160 patients underwent surgical lung biopsy (SLB). The multidisciplinary team (MDT) determined a diagnosis with high or low confidence, and a management strategy, both before and after the LBx data. Results Final MDT diagnoses were 189 idiopathic pulmonary fibrosis (IPF), 143 non-IPF fibrotic ILDs, and 94 nonfibrotic ILDs. LBx data changed the management strategy in 145 cases (34%), with similar results for TBLC and SLB (the treatment strategy changed in 31.5% of TBLC cases, 84/266, P < 0.001, and in 38% of SLB, 61/160, P < 0.001). After LBx, the MDT was less inclined to “wait and see” (from 15% to 4% of cases, P < 0.001) or to prescribe steroids only (from 54% to 37%, P < 0.001) and was more confident to treat with antifibrotics (from 23% to 44%, P < 0.001) or immunosuppressive drugs (from 7% to 14%, P < 0.001). The therapeutic strategy changed in 70% of reclassified cases (60/85) and in 59% of cases in which LBx increased the MDT confidence (84/142). Reclassification significantly impacted the outcome. The cases classified as non-IPF by clinician and radiologist and then reclassified to be IPF after LBx showed a significantly worse survival compared with non-IPF confirmed cases (adjusted hazard ratio [HR], 3.8; 95% confidence interval [CI], 1.75–8.3); P = 0.001. Cases initially classified as IPF and then reclassified as non-IPF after LBx showed a better prognosis compared with IPF confirmed cases (HR, 0.41; 95% CI, 0.18–0.94; P = 0.03). Conclusions Reclassification of cases with LBx data increased diagnostic confidence and changed the therapeutic strategy in one-third of cases. Pathologic reclassification of cases refined prognosis prediction. Patients classified as non-IPF by clinician and radiologist and then reclassified IPF after LBx had worse prognosis compared with the non-IPF confirmed cases.
Samuel Alan Yousem, MD (October 17, 1956 to August 17, 2021)
Colby, Thomas V., Myers, Jeffrey L., Colby, Thomas V., Myers, Jeffrey L.

Mayo Clinic

American Journal of Surgical Pathology | October 11, 2021 | Volume: 45 | Issue: 12 | Pages: 1732-1733

10.1097/pas.0000000000001823 Get It

Diagnostic Accuracy of Endobronchial Optical Coherence Tomography for the Microscopic Diagnosis of Usual Interstitial Pneumonia
Nandy, Sreyankar , Raphaely, Rebecca A., Muniappan, Ashok, Shih, Angela, Roop, Benjamin W., Sharma, Amita, Keyes, Colleen M., Colby, Thomas V., Auchincloss, Hugh G., Gaissert, Henning A., Lanuti, Michael, Morse, Christopher R., Ott, Harald C., Wain, John C., Wright, Cameron D., Garcia-Moliner, Maria L., Smith, Maxwell L., VanderLaan, Paul A., Berigei, Sarita R., Mino-Kenudson, Mari, Horick, Nora K., Liang, Lloyd L., Davies, Diane L., Szabari, Margit V., Caravan, Peter, Medoff, Benjamin D., Tager, Andrew M., Suter, Melissa J., Hariri, Lida P., Horick, Nora , Liang, Lloyd L. , VanderLaan, Paul A. , Shih, Angela , Nandy, Sreyankar , Raphaely, Rebecca A., Muniappan, Ashok, Roop, Benjamin W., Sharma, Amita, Keyes, Colleen M., Colby, Thomas V., Auchincloss, Hugh G., Gaissert, Henning A., Lanuti, Michael, Morse, Christopher R., Ott, Harald C., Wain, John C., Wright, Cameron D., Garcia-Moliner, Maria L., Smith, Maxwell L., Berigei, Sarita R., Mino-Kenudson, Mari, Liang, Lloyd L., Davies, Diane L., Szabari, Margit V., Caravan, Peter, Medoff, Benjamin D., Tager, Andrew M., Suter, Melissa J., Hariri, Lida P., Shih, Angela , Horick, Nora

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | August 10, 2021 | Volume: 204 | Issue: 10 | Pages: 1164-1179

10.1164/rccm.202104-0847oc | PMID 34375171 Get It

Abstract Rationale Early, accurate diagnosis of interstitial lung disease (ILD) informs prognosis and therapy, especially in idiopathic pulmonary fibrosis (IPF). Current diagnostic methods are imperfect. High-resolution computed tomography has limited resolution, and surgical lung biopsy (SLB) carries risks of morbidity and mortality. Endobronchial optical coherence tomography (EB-OCT) is a low-risk, bronchoscope-compatible modality that images large lung volumes in vivo with microscopic resolution, including subpleural lung, and has the potential to improve the diagnostic accuracy of bronchoscopy for ILD diagnosis. Objectives We performed a prospective diagnostic accuracy study of EB-OCT in patients with ILD with a low-confidence diagnosis undergoing SLB. The primary endpoints were EB-OCT sensitivity/specificity for diagnosis of the histopathologic pattern of usual interstitial pneumonia (UIP) and clinical IPF. The secondary endpoint was agreement between EB-OCT and SLB for diagnosis of the ILD fibrosis pattern. Methods EB-OCT was performed immediately before SLB. The resulting EB-OCT images and histopathology were interpreted by blinded, independent pathologists. Clinical diagnosis was obtained from the treating pulmonologists after SLB, blinded to EB-OCT. Measurements and Main Results We enrolled 31 patients, and 4 were excluded because of inconclusive histopathology or lack of EB-OCT data. Twenty-seven patients were included in the analysis (16 men, average age: 65.0 yr): 12 were diagnosed with UIP and 15 with non-UIP ILD. Average FVC and Dl CO were 75.3% (SD, 18.5) and 53.5% (SD, 16.4), respectively. Sensitivity and specificity of EB-OCT was 100% (95% confidence interval, 75.8–100.0%) and 100% (79.6–100%), respectively, for both histopathologic UIP and clinical diagnosis of IPF. There was high agreement between EB-OCT and histopathology for diagnosis of ILD fibrosis pattern (weighted κ: 0.87 [0.72–1.0]). Conclusions EB-OCT is a safe, accurate method for microscopic ILD diagnosis, as a complement to high-resolution computed tomography and an alternative to SLB.
Small Airway Reduction and Fibrosis Is an Early Pathologic Feature of Idiopathic Pulmonary Fibrosis
Ikezoe, Kohei , Peterson, S. , Prins, D. A., Hague, Cameron , Murphy, Darra , Ledoux, Stacey, Chu, Fanny, Xu, Feng , Cooper, Joel D. , Tanabe, Naoya , Ryerson, Christopher J. , Paré, Peter D., Coxson, Harvey O. , Colby, Thomas V. , Hogg, James C. , Vasilescu, Dragoş M. , Tanabe, Naoya , Vasilescu, Dragoş M , Hackett, Tillie‐Louise , Prins, Dante

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | August 3, 2021 | Volume: 204 | Issue: 9 | Pages: 1048-1059

10.1164/rccm.202103-0585oc | PMID 34343057 Get It

Abstract Rationale To improve disease outcomes in idiopathic pulmonary fibrosis (IPF), it is essential to understand its early pathophysiology so that it can be targeted therapeutically. Objectives Perform three-dimensional assessment of the IPF lung microstructure using stereology and multiresolution computed tomography (CT) imaging. Methods Explanted lungs from patients with IPF (n = 8) and donor control subjects (n = 8) were inflated with air and frozen. CT scans were used to assess large airways. Unbiased, systematic uniform random samples (n = 8/lung) were scanned with microCT for stereological assessment of small airways (count number, and measure airway wall and lumen area) and parenchymal fibrosis (volume fraction of tissue, alveolar surface area, and septal wall thickness). Measurements and Main Results The total number of airways on clinical CT was greater in IPF lungs than control lungs (P < 0.01), owing to an increase in the wall (P < 0.05) and lumen area (P < 0.05) resulting in more visible airways with a lumen larger than 2 mm. In IPF tissue samples without microscopic fibrosis, assessed by the volume fraction of tissue using microCT, there was a reduction in the number of the terminal (P < 0.01) and transitional (P < 0.001) bronchioles, and an increase in terminal bronchiole wall area (P < 0.001) compared with control lungs. In IPF tissue samples with microscopic parenchymal fibrosis, terminal bronchioles had increased airway wall thickness (P < 0.05) and dilated airway lumens (P < 0.001) leading to honeycomb cyst formations. Conclusions This study has important implications for the current thinking on how the lung tissue is remodeled in IPF and highlights small airways as a potential target to modify IPF outcomes.
Stereological Assessment of Parenchyma and Small Airway Morphology Using Micro-Computed Tomography in Patients with Idiopathic Pulmonary Fibrosis
Peterson, S. , Prins, D., Hague, C., Murphy, Darra , Xu, Fan , Tanabe, N., Coxson, Harvey O. , Colby, Thomas V. , Hogg, James C. , Vasilescu, Dragoş M. , Ikezoe, Kohei , Cooper, Jonathan D. , Hackett, Tillie‐Louise

Mayo Clinic

TP126. TP126 STRUCTURE AND FUNCTION IN PARENCHYMAL LUNG DISEASES | May 4, 2021 | Volume: No volume available | Issue: No issue available | Pages: A4650-A4650

10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a4650 Get It

Envisia Genomic Classifier Demonstrates Consistent Performance Across Gender, Age Group, and Smoking Status
Scholand, Mary Beth , Lynch, David A. , Colby, Thomas V. , Groshong, Steve D. , Chung, Jiwhey, Pankratz, D., Walsh, Simon , Lofaro, Lori , Huang, Jing , Bhorade, Sangeeta , Martinez, F.J., Raghu, Ganesh , group, BRAVE study, Richeldi, Luca , Myers, Jeffrey L. , Walsh, S., Kennedy, G.

Mayo Clinic

TP26. TP026 DIAGNOSIS, ASSESSMENT, AND PROGNOSIS OF FIBROTIC ILD | May 4, 2021 | Volume: No volume available | Issue: No issue available | Pages: A1839-A1839

10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a1839 Get It

Envisia Genomic Classifier Helps Improve Multidisciplinary Diagnoses of Complex Interstitial Lung Diseases
Lancaster, Lisa , Lynch, David A. , Colby, Thomas V. , Lofaro, Lori , Pankratz, Daniel G., Walsh, Simon, Huang, Jing , Burbanks-Ivey, J., Bhorade, Sangeeta , group, BRAVE study, Kennedy, G.

Mayo Clinic

TP27. TP027 DIFFUSE PARENCHYMAL LUNG DISEASE: PATIENT CHARACTERISTICS AND OUTCOMES | May 4, 2021 | Volume: No volume available | Issue: No issue available | Pages: A1877-A1877

10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a1877 Get It

Prognostic and Clinical Value of Cluster Analysis in Idiopathic Pleuroparenchymal Fibroelastosis Phenotypes
Nakamura, Yutaro , Mori, Kazutaka , Enomoto, Yasunori , Kono, Masato , Sumikawa, Hiromitsu , Johkoh, Takeshi , Colby, Thomas V. , Hozumi, Hironao , Fujisawa, Tomoyuki , Enomoto, Noriyuki , Inui, Naoki , Kaida, Yusuke , Yokomura, Koshi, Koshimizu, Naoki, Toyoshima, Mikio , Imokawa, Shiro , Shirai, Toshihiro , Hayakawa, Hiroshi , Suda, Takafumi , Hozumi, Hironao , Suzuki, Yuzo , Fujisawa, Tomoyuki , Yasui, Hideki , Karayama, Masato , Furuhashi, Kazuki , Yamada, Takashi , Nakamura, Hidenori

Mayo Clinic

Journal of Clinical Medicine | April 5, 2021 | Volume: 10 | Issue: 7 | Pages: 1498

10.3390/jcm10071498 | PMID 33916508 Get It

Idiopathic pleuroparenchymal fibroelastosis (PPFE) is a distinctive interstitial pneumonia with upper lobe predominance that shows unique morphological features among idiopathic interstitial pneumonias (IIPs). Affected patients have a variety of clinical presentations with heterogeneous clinical courses. Cluster analysis is a valuable tool for identifying distinct clinical phenotypes under heterogeneous conditions. This study aimed to identify the phenotypes of patients with idiopathic PPFE. Using cluster analysis, novel PPFE phenotypes were identified among subjects from our multicenter cohort, and outcomes were stratified according to phenotypic clusters. Among the subjects with baseline data (N = 84), four clusters were identified. Cluster 1 included younger male subjects with coexisting non-UIP-like patterns. Cluster 2 included elderly female nonsmokers with low body mass index (BMI). Cluster 3 included elderly male smokers with a coexisting IP-like pattern. Cluster 4 included younger male smokers without lower lobe lesions. Patients in cluster 3 had significantly worse survival outcomes than those in clusters 1, 2, and 4 (p < 0.001, p = 0.0041, and p = 0.0155, respectively). Among idiopathic PPFE patients, cluster analysis using baseline characteristics identified four distinct clinical phenotypes that might predict survival outcomes.
Guidelines for Pathologic Diagnosis of Malignant Mesothelioma: A Consensus Statement from the International Mesothelioma Interest Group
Husain, Aliya N. , Colby, Thomas V. , Ordóǹez, Nelson G., Krausz, Thomas, Borczuk, Alain , Cagle, Philip T., Gibbs, A R, Gown, Allen M. , Hammar, Samuel P. , Litzky, Leslie A., Roggli, Victor L., Chirieac, Lucian R. , Churg, Andrew , Galateau-Sallé, Françoise , Travis, William D. , Wick, Mark R.

Mayo Clinic

Archives of Pathology & Laboratory Medicine | February 12, 2021 | Volume: 133 | Issue: 8 | Pages: 1317-1331

10.5858/133.8.1317 | PMID 19653732 Get It

Abstract Context. —Malignant mesothelioma (MM) is an uncommon tumor that can be difficult to diagnose. Objective. —To develop practical guidelines for the pathologic diagnosis of MM. Data Sources. —A pathology panel was convened at the International Mesothelioma Interest Group biennial meeting (October 2006). Pathologists with an interest in the field also contributed after the meeting. Conclusions. —There was consensus opinion regarding (1) distinguishing benign from malignant mesothelial proliferations (both epithelioid and spindle cell lesions), (2) cytologic diagnosis of MM, (3) key histologic features of pleural and peritoneal MM, (4) use of histochemical and immunohistochemical stains in the diagnosis and differential diagnosis of MM, (5) differentiating epithelioid MM from various carcinomas (lung, breast, ovarian, and colonic adenocarcinomas and squamous cell and renal cell carcinomas), (6) diagnosis of sarcomatoid mesothelioma, (7) use of molecular markers in the differential diagnosis of MM, (8) electron microscopy in the diagnosis of MM, and (9) some caveats and pitfalls in the diagnosis of MM. Immunohistochemical panels are integral to the diagnosis of MM, but the exact makeup of panels used is dependent on the differential diagnosis and on the antibodies available in a given laboratory. Immunohistochemical panels should contain both positive and negative markers. The International Mesothelioma Interest Group recommends that markers have either sensitivity or specificity greater than 80% for the lesions in question. Interpretation of positivity generally should take into account the localization of the stain (eg, nuclear versus cytoplasmic) and the percentage of cells staining (>10% is suggested for cytoplasmic membranous markers). These guidelines are meant to be a practical reference for the pathologist.